Crinetics Stock Based Compensation from 2010 to 2025

CRNX Stock

USD 34.90 0.39 1.13%

Crinetics Pharmaceuticals Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2025. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2017-03-31

Previous Quarter

18.1 M

Current Value

18.8 M

Quarterly Volatility

5.7 M

Covid

Check Crinetics Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crinetics Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 43.5 M, Interest Income of 43.5 M or Depreciation And Amortization of 760.2 K, as well as many indicators such as Price To Sales Ratio of 4.2 K, Dividend Yield of 0.0 or PTB Ratio of 3.27. Crinetics financial statements analysis is a perfect complement when working with Crinetics Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Crinetics Pharmaceuticals Correlation against competitors.

For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.

Latest Crinetics Pharmaceuticals' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Crinetics Pharmaceuticals over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Crinetics Pharmaceuticals' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crinetics Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Crinetics Stock Based Compensation Regression Statistics

	Arithmetic Mean	15,625,019
	Geometric Mean	2,252,159
	Coefficient Of Variation	158.04
	Mean Deviation	18,834,151
	Median	2,320,000
	Standard Deviation	24,693,272
	Sample Variance	609.8T
	Range	72.6M
	R-Value	0.82
	Mean Square Error	218.6T
	R-Squared	0.67
	Significance	0.0001
	Slope	4,231,010
	Total Sum of Squares	9146.4T

Crinetics Stock Based Compensation History

	2025	72.9 M
	2024	69.4 M
	2023	40.9 M
	2022	28.3 M
	2021	17.4 M
	2020	10.4 M
	2019	6.3 M

Other Fundumenentals of Crinetics Pharmaceuticals

Stock Based Compensation To Revenue

Crinetics Pharmaceuticals Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Long Term Debt Total	Capital Surpluse	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Invested Capital	Net Working Capital	Short Term Investments	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue
Total Assets		0.89	0.82	-0.8	-0.97	0.63	-0.89	0.96	-0.89	0.69	0.93	-0.89	1.0	0.99	0.99	0.57	1.0	1.0	0.98	-0.66	0.99	0.83
Total Stockholder Equity	0.89		0.5	-0.6	-0.81	0.32	-0.88	0.88	-0.88	0.38	0.91	-0.88	0.89	0.93	0.86	0.26	0.88	0.89	0.94	-0.34	0.86	0.66
Net Tangible Assets	0.82	0.5		-0.75	-0.89	0.86	-0.56	0.82	-0.56	0.92	0.71	-0.56	0.82	0.77	0.85	0.84	0.83	0.82	0.71	-0.88	0.85	0.78
Net Debt	-0.8	-0.6	-0.75		0.72	-0.45	0.72	-0.66	0.72	-0.67	-0.57	0.72	-0.81	-0.72	-0.78	-0.57	-0.81	-0.81	-0.7	0.64	-0.78	-0.42
Retained Earnings	-0.97	-0.81	-0.89	0.72		-0.76	0.77	-0.97	0.77	-0.73	-0.94	0.77	-0.96	-0.96	-0.99	-0.64	-0.96	-0.96	-0.94	0.75	-0.99	-0.91
Accounts Payable	0.63	0.32	0.86	-0.45	-0.76		-0.32	0.69	-0.32	0.87	0.59	-0.32	0.63	0.61	0.69	0.9	0.64	0.62	0.54	-0.93	0.69	0.76
Long Term Debt	-0.89	-0.88	-0.56	0.72	0.77	-0.32		-0.78	1.0	-0.45	-0.79	1.0	-0.89	-0.87	-0.86	-0.29	-0.89	-0.89	-0.91	0.41	-0.86	-0.63
Net Receivables	0.96	0.88	0.82	-0.66	-0.97	0.69	-0.78		-0.78	0.7	0.97	-0.78	0.95	0.98	0.96	0.6	0.95	0.95	0.94	-0.68	0.96	0.86
Long Term Debt Total	-0.89	-0.88	-0.56	0.72	0.77	-0.32	1.0	-0.78		-0.45	-0.79	1.0	-0.89	-0.87	-0.86	-0.29	-0.89	-0.89	-0.91	0.41	-0.86	-0.63
Capital Surpluse	0.69	0.38	0.92	-0.67	-0.73	0.87	-0.45	0.7	-0.45		0.53	-0.45	0.69	0.65	0.7	0.97	0.71	0.69	0.55	-0.89	0.7	0.6
Total Liab	0.93	0.91	0.71	-0.57	-0.94	0.59	-0.79	0.97	-0.79	0.53		-0.79	0.92	0.97	0.94	0.42	0.92	0.92	0.95	-0.55	0.94	0.88
Short Long Term Debt	-0.89	-0.88	-0.56	0.72	0.77	-0.32	1.0	-0.78	1.0	-0.45	-0.79		-0.89	-0.87	-0.86	-0.29	-0.89	-0.89	-0.91	0.41	-0.86	-0.63
Total Current Assets	1.0	0.89	0.82	-0.81	-0.96	0.63	-0.89	0.95	-0.89	0.69	0.92	-0.89		0.98	0.99	0.57	1.0	1.0	0.98	-0.66	0.99	0.82
Short Term Debt	0.99	0.93	0.77	-0.72	-0.96	0.61	-0.87	0.98	-0.87	0.65	0.97	-0.87	0.98		0.98	0.53	0.98	0.98	0.98	-0.62	0.98	0.83
Common Stock	0.99	0.86	0.85	-0.78	-0.99	0.69	-0.86	0.96	-0.86	0.7	0.94	-0.86	0.99	0.98		0.59	0.99	0.99	0.97	-0.71	1.0	0.86
Property Plant Equipment	0.57	0.26	0.84	-0.57	-0.64	0.9	-0.29	0.6	-0.29	0.97	0.42	-0.29	0.57	0.53	0.59		0.58	0.56	0.42	-0.91	0.59	0.51
Net Invested Capital	1.0	0.88	0.83	-0.81	-0.96	0.64	-0.89	0.95	-0.89	0.71	0.92	-0.89	1.0	0.98	0.99	0.58		1.0	0.97	-0.67	0.99	0.82
Net Working Capital	1.0	0.89	0.82	-0.81	-0.96	0.62	-0.89	0.95	-0.89	0.69	0.92	-0.89	1.0	0.98	0.99	0.56	1.0		0.98	-0.65	0.99	0.81
Short Term Investments	0.98	0.94	0.71	-0.7	-0.94	0.54	-0.91	0.94	-0.91	0.55	0.95	-0.91	0.98	0.98	0.97	0.42	0.97	0.98		-0.53	0.97	0.84
Deferred Long Term Liab	-0.66	-0.34	-0.88	0.64	0.75	-0.93	0.41	-0.68	0.41	-0.89	-0.55	0.41	-0.66	-0.62	-0.71	-0.91	-0.67	-0.65	-0.53		-0.71	-0.63
Capital Stock	0.99	0.86	0.85	-0.78	-0.99	0.69	-0.86	0.96	-0.86	0.7	0.94	-0.86	0.99	0.98	1.0	0.59	0.99	0.99	0.97	-0.71		0.86
Current Deferred Revenue	0.83	0.66	0.78	-0.42	-0.91	0.76	-0.63	0.86	-0.63	0.6	0.88	-0.63	0.82	0.83	0.86	0.51	0.82	0.81	0.84	-0.63	0.86

Click cells to compare fundamentals

About Crinetics Pharmaceuticals Financial Statements

Crinetics Pharmaceuticals investors use historical fundamental indicators, such as Crinetics Pharmaceuticals' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Crinetics Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Stock Based Compensation	69.4 M	72.9 M
Stock Based Compensation To Revenue	66.78	70.12

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Crinetics Stock Based Compensation from 2010 to 2025

Latest Crinetics Pharmaceuticals' Stock Based Compensation Growth Pattern

Crinetics Stock Based Compensation Regression Statistics

Crinetics Stock Based Compensation History

Other Fundumenentals of Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Stock Based Compensation component correlations

About Crinetics Pharmaceuticals Financial Statements

Also Currently Popular

Additional Tools for Crinetics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY